AstraZeneca in broad drug deal with Bicycle worth up to $1 bln

LONDON (Reuters) - AstraZeneca has signed a wide-ranging deal with private biotech firm Bicycle Therapeutics to develop a novel class of small molecule medicines for treating respiratory, cardiovascular and metabolic diseases.